On the basis of geographical analysis, the global rubella treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market North America industry is estimated to hold largest revenue share by 2036, on account of growing levels of awareness about rubella, high healthcare spending, and rising number of drug manufacturing facilities in the region. The Centers for Medicare and Medicaid Services stated that in 2019, the healthcare expenditure in the United States reached a value of USD 11,582 per person in 2019. It accounted for 17.7 percent of the nation’s GDP that same year.
In addition, Europe is anticipated to be the second largest shareholder in the market during the forecast period owing to stringent regulatory framework and government guidelines regarding the health of mother and child. Moreover, the rubella treatment market in Asia Pacific is expected to witness noteworthy growth by the end of 2030, which can be credited to the increasing government initiatives to develop novel vaccines and therapies, and relatively low cost of drug production in the region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?